When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MKGAY - Immutep reports encouraging preliminary data on lead drug eftilagimod alpha
Merck KGaA ADR
Immutep Limited (NASDAQ:IMMP) jumps 36% premarket on average volume in reaction to preliminary results from a Frankfurt, Germany-based Phase 1 clinical trial evaluating the combination of lead candidate eftilagimod alpha and Pfizer (NYSE:PFE) and Merck KGaA's (OTCPK:MKGAY) PD-L1 inhibitor avelumab in 12 heavily pretreated patients with solid tumors, primarily gastrointestinal cancers. The data were virtually presented at ASCO.
More news on: Immutep Limited, Pfizer Inc., Merck KGaA ADR, Healthcare stocks news, Stocks on the move,